Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ondansetron clinical pharmacokinetics

F Roila1, A Del Favero

  • 1Medical Oncology Division, Policlinico Hospital, Perugia, Italy.

Clinical Pharmacokinetics
|August 1, 1995
PubMed
Summary

Ondansetron effectively prevents chemotherapy-induced nausea and vomiting by blocking serotonin 5-HT3 receptors. Optimal dosing and scheduling for ondansetron (a serotonin 5-HT3-receptor antagonist) require further investigation to ensure maximum antiemetic control.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2021
Same author

Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

MASCC/ESMO Antiemetic Guidelines: Introduction to the 2016 guideline update.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2016
Same author

A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.

Critical reviews in oncology/hematology·2015

Area of Science:

  • Pharmacology
  • Gastroenterology

Background:

  • Ondansetron is a selective serotonin 5-HT3-receptor antagonist.
  • It demonstrates significant antiemetic activity and good tolerability for chemotherapy-induced nausea and vomiting (CINV).

Purpose of the Study:

  • To review the pharmacokinetics and pharmacodynamics of ondansetron.
  • To discuss its efficacy in managing CINV and identify areas for further research.

Main Methods:

  • Literature review of ondansetron's absorption, distribution, metabolism, and excretion.
  • Analysis of clinical data regarding its antiemetic effects and tolerability.

Main Results:

  • Ondansetron is rapidly absorbed orally, with bioavailability reduced by hepatic first-pass metabolism.
  • Peak concentrations are reached in 0.5-2 hours, necessitating administration at least 30 minutes before chemotherapy.
  • Elimination half-life is approximately 3.8 hours, with clearance primarily via hepatic metabolism.

Conclusions:

  • Ondansetron is an effective antiemetic for CINV.
  • Further research is needed to determine the optimal dose and schedule for maximal emesis control, considering systemic availability.

Related Experiment Videos